HIV-associated malignancies in sub-Saharan Africa: Progress, challenges, and opportunities

Research output: Research - peer-reviewReview article

  • 2 Citations

Abstract

Purpose of review: To summarize recent developments for HIV-associated malignancies (HIVAM) in low-income and middleincome countries (LMIC) with particular focus on sub-Saharan Africa (SSA). Recent findings: Antiretroviral therapy (ART) scale-up is leading to epidemiologic transitions in LMIC similar to high-income countries, with aging and growth of HIV-infected populations, declining infectious deaths, increasing cancer deaths, and transitions from AIDS-defining cancers to non-AIDS defining cancers. Despite ART scaleup, the HIVAM burden remains high including an enormous AIDS-defining cancers burden in SSA. For Kaposi sarcoma, patients treated with ART and chemotherapy can experience good outcomes even in rural SSA, but Kaposi sarcoma heterogeneity remains insufficiently understood including virologic, immunologic, and inflammatory features that may be unique to LMIC. For cervical cancer, scale-up of prevention efforts including vaccination and screening is underway, with benefits already apparent despite continuing high disease burden. For non-Hodgkin lymphoma, curative treatment is possible in the ART era even in SSA, and multifaceted approaches can improve outcomes further. For many other prevalent HIVAM, care and research efforts are being established to guide treatment and prevention specifically in LMIC. Summary: Sustained investment for HIVAM in LMIC can help catalyze a cancer care and research agenda that benefits HIV-positive and HIV-negative patients worldwide.

LanguageEnglish (US)
Pages89-95
Number of pages7
JournalCurrent Opinion in HIV and AIDS
Volume12
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Africa South of the Sahara
HIV
Neoplasms
Therapeutics
Kaposi's Sarcoma
Acquired Immunodeficiency Syndrome
Research
Uterine Cervical Neoplasms
Non-Hodgkin's Lymphoma
Vaccination
Drug Therapy
Growth
Population

Keywords

  • Cervical cancer
  • HIV-associated malignancies
  • Kaposi sarcoma
  • Low-income and middle-income countries
  • Non-Hodgkin lymphoma
  • Sub-Saharan Africa

ASJC Scopus subject areas

  • Immunology
  • Hematology
  • Oncology
  • Oncology(nursing)
  • Infectious Diseases
  • Virology

Cite this

HIV-associated malignancies in sub-Saharan Africa : Progress, challenges, and opportunities. / Chinula, Lameck; Moses, Agnes; Gopal, Satish.

In: Current Opinion in HIV and AIDS, Vol. 12, No. 1, 2017, p. 89-95.

Research output: Research - peer-reviewReview article

@article{6c061ede31924915b437fb9a237ad5cd,
title = "HIV-associated malignancies in sub-Saharan Africa: Progress, challenges, and opportunities",
abstract = "Purpose of review: To summarize recent developments for HIV-associated malignancies (HIVAM) in low-income and middleincome countries (LMIC) with particular focus on sub-Saharan Africa (SSA). Recent findings: Antiretroviral therapy (ART) scale-up is leading to epidemiologic transitions in LMIC similar to high-income countries, with aging and growth of HIV-infected populations, declining infectious deaths, increasing cancer deaths, and transitions from AIDS-defining cancers to non-AIDS defining cancers. Despite ART scaleup, the HIVAM burden remains high including an enormous AIDS-defining cancers burden in SSA. For Kaposi sarcoma, patients treated with ART and chemotherapy can experience good outcomes even in rural SSA, but Kaposi sarcoma heterogeneity remains insufficiently understood including virologic, immunologic, and inflammatory features that may be unique to LMIC. For cervical cancer, scale-up of prevention efforts including vaccination and screening is underway, with benefits already apparent despite continuing high disease burden. For non-Hodgkin lymphoma, curative treatment is possible in the ART era even in SSA, and multifaceted approaches can improve outcomes further. For many other prevalent HIVAM, care and research efforts are being established to guide treatment and prevention specifically in LMIC. Summary: Sustained investment for HIVAM in LMIC can help catalyze a cancer care and research agenda that benefits HIV-positive and HIV-negative patients worldwide.",
keywords = "Cervical cancer, HIV-associated malignancies, Kaposi sarcoma, Low-income and middle-income countries, Non-Hodgkin lymphoma, Sub-Saharan Africa",
author = "Lameck Chinula and Agnes Moses and Satish Gopal",
year = "2017",
doi = "10.1097/COH.0000000000000329",
volume = "12",
pages = "89--95",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - HIV-associated malignancies in sub-Saharan Africa

T2 - Current Opinion in HIV and AIDS

AU - Chinula,Lameck

AU - Moses,Agnes

AU - Gopal,Satish

PY - 2017

Y1 - 2017

N2 - Purpose of review: To summarize recent developments for HIV-associated malignancies (HIVAM) in low-income and middleincome countries (LMIC) with particular focus on sub-Saharan Africa (SSA). Recent findings: Antiretroviral therapy (ART) scale-up is leading to epidemiologic transitions in LMIC similar to high-income countries, with aging and growth of HIV-infected populations, declining infectious deaths, increasing cancer deaths, and transitions from AIDS-defining cancers to non-AIDS defining cancers. Despite ART scaleup, the HIVAM burden remains high including an enormous AIDS-defining cancers burden in SSA. For Kaposi sarcoma, patients treated with ART and chemotherapy can experience good outcomes even in rural SSA, but Kaposi sarcoma heterogeneity remains insufficiently understood including virologic, immunologic, and inflammatory features that may be unique to LMIC. For cervical cancer, scale-up of prevention efforts including vaccination and screening is underway, with benefits already apparent despite continuing high disease burden. For non-Hodgkin lymphoma, curative treatment is possible in the ART era even in SSA, and multifaceted approaches can improve outcomes further. For many other prevalent HIVAM, care and research efforts are being established to guide treatment and prevention specifically in LMIC. Summary: Sustained investment for HIVAM in LMIC can help catalyze a cancer care and research agenda that benefits HIV-positive and HIV-negative patients worldwide.

AB - Purpose of review: To summarize recent developments for HIV-associated malignancies (HIVAM) in low-income and middleincome countries (LMIC) with particular focus on sub-Saharan Africa (SSA). Recent findings: Antiretroviral therapy (ART) scale-up is leading to epidemiologic transitions in LMIC similar to high-income countries, with aging and growth of HIV-infected populations, declining infectious deaths, increasing cancer deaths, and transitions from AIDS-defining cancers to non-AIDS defining cancers. Despite ART scaleup, the HIVAM burden remains high including an enormous AIDS-defining cancers burden in SSA. For Kaposi sarcoma, patients treated with ART and chemotherapy can experience good outcomes even in rural SSA, but Kaposi sarcoma heterogeneity remains insufficiently understood including virologic, immunologic, and inflammatory features that may be unique to LMIC. For cervical cancer, scale-up of prevention efforts including vaccination and screening is underway, with benefits already apparent despite continuing high disease burden. For non-Hodgkin lymphoma, curative treatment is possible in the ART era even in SSA, and multifaceted approaches can improve outcomes further. For many other prevalent HIVAM, care and research efforts are being established to guide treatment and prevention specifically in LMIC. Summary: Sustained investment for HIVAM in LMIC can help catalyze a cancer care and research agenda that benefits HIV-positive and HIV-negative patients worldwide.

KW - Cervical cancer

KW - HIV-associated malignancies

KW - Kaposi sarcoma

KW - Low-income and middle-income countries

KW - Non-Hodgkin lymphoma

KW - Sub-Saharan Africa

UR - http://www.scopus.com/inward/record.url?scp=84986193001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986193001&partnerID=8YFLogxK

U2 - 10.1097/COH.0000000000000329

DO - 10.1097/COH.0000000000000329

M3 - Review article

VL - 12

SP - 89

EP - 95

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 1

ER -